GlassScriptPhysician profile
Arch Aaron P Amon
NPI 1447527346
$9,432.70
in general payments reported to CMS, 2019-2025
19 companies · $3,360 in 2025
The $3,360 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,263 · 2020: $313 · 2021: $398 · 2022: $1,483 · 2023: $802 · 2024: $1,812 · 2025: $3,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,700 · Food and Beverage: $2,455 · Gift: $820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,700.00 |
| Food and Beverage | $2,454.54 |
| Gift | $820.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $2,733.60 | 2022-2025 | S-217622 |
| Sekisui Diagnostics LLC | $1,420.00 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $1,312.36 | 2019-2024 | Xarelto |
| Amgen INC. | $815.78 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $734.08 | 2020-2025 | Breztri |
| Novartis Pharmaceuticals Corporation | $330.39 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.29 | 2022-2025 | Jardiance |
| Becton, Dickinson and Company | $300.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $235.32 | 2019-2024 | Camzyos |
| Pfizer INC. | $191.39 | 2019-2020 | |
| United Therapeutics Corporation | $187.33 | 2024-2025 | |
| Glaxosmithkline, LLC. | $146.68 | 2021-2022 | |
| Portola Pharmaceuticals, LLC | $142.04 | 2019 | |
| Edwards Lifesciences Corporation | $139.35 | 2022 | |
| Merck Sharp & Dohme LLC | $130.20 | 2023-2024 | Verquvo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $124.99 | 2024 | Givlaari |
| Vertex Pharmaceuticals Incorporated | $86.46 | 2025 | |
| Veloxis Pharmaceuticals, INC. | $66.66 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arch Aaron Amon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.